A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients . Clinics, [S. l.], v. 71, n. 10, p. 586–592, 2016. DOI: 10.6061/clinics/2016(10)06. Disponível em: https://www.revistas.usp.br/clinics/article/view/122233.. Acesso em: 4 jun. 2024.